Thiotepa
| Clinical data | |||
|---|---|---|---|
| Trade names | Tepadina | ||
| Other names | N,N',N''(-triethylenethiophosphoramide, INN, Thiotepa, Tepadina, Tepylute | ||
| AHFS/Drugs.com | Monograph | ||
| MedlinePlus | a682821 | ||
| License data | |||
| Pregnancy category |
| ||
| Routes of administration | Intravenous, intracavitary, intravesical | ||
| ATC code | |||
| Legal status | |||
| Legal status | |||
| Pharmacokinetic data | |||
| Metabolism | Liver (CYP2B6, CYP3A) | ||
| Metabolites | Phase 1: Tetraethylenepentamine (tepa) Phase 2: Thiotepa-mercapturate | ||
| Elimination half-life | 1.5–4.1 hours | ||
| Excretion | Kidney 6 hours for thiotepa 8 hours for TEPA | ||
| Identifiers | |||
| |||
| CAS Number | |||
| PubChem CID | |||
| IUPHAR/BPS | |||
| DrugBank | |||
| ChemSpider | |||
| UNII | |||
| KEGG | |||
| ChEMBL | |||
| CompTox Dashboard (EPA) | |||
| ECHA InfoCard | 100.000.124 | ||
| Chemical and physical data | |||
| Formula | C6H12N3PS | ||
| Molar mass | 189.22 g/mol g·mol−1 | ||
| 3D model (JSmol) | |||
| Melting point | 51.5 °C (124.7 °F) | ||
| Solubility in water | 0.19 g/mL (water, 25 °C) Freely soluble in alcohol, diethyl ether and chloroform mg/mL (20 °C) | ||
| |||
| |||
| (what is this?) (verify) | |||
Thiotepa (N,N',N''(-triethylenethiophosphoramide, INN), sold under the brand name Tepadina among others, is an anti-cancer medication.
Thiotepa is an organophosphorus compound with the formula (C2H4N)3PS.